Cargando…

Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study

The use of adjuvant therapy has provided survival benefits in patients with advanced melanoma. This study aimed to explore the recurrence and prognosis of the PD-1 inhibitor, conventional interferon (IFN), or observation (OBS) on resected stage III acral and cutaneous melanoma patients through a ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tong, Xu, Yu, Sun, Wei, Yan, Wangjun, Wang, Chunmeng, Hu, Tu, Zhang, Xiaowei, Luo, Zhiguo, Liu, Xin, Chen, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867270/ https://www.ncbi.nlm.nih.gov/pubmed/36678538 http://dx.doi.org/10.3390/ph16010041

Ejemplares similares

A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
por: Sun, Wei, et al.
Publicado: (2023)

Comparative analysis of adjuvant therapy for stage III BRAF‐mut melanoma: A real‐world retrospective study from single center in China
por: Zhong, Jingqin, et al.
Publicado: (2023)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
por: Livingstone, Ann, et al.
Publicado: (2021)

Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
por: Livingstone, Ann, et al.
Publicado: (2023)

Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis
por: Hoffmann, Michèle, et al.
Publicado: (2022)

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
por: De Meza, Melissa M., et al.
Publicado: (2023)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Factors associated with the use of adjuvant radiation therapy in stage III melanoma
por: King, Amber L. O., et al.
Publicado: (2023)

Survival impact of immediate complete lymph node dissection for Chinese acral and cutaneous melanoma with micrometastasis in sentinel nodes: a retrospective study
por: Zhong, Jingqin, et al.
Publicado: (2023)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
por: Sun, Lillian, et al.
Publicado: (2018)

IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
por: Fukuda, Keitaro
Publicado: (2023)

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma
por: Derks, S.H.A.E., et al.
Publicado: (2022)

An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma
por: Lorenzi, Maria, et al.
Publicado: (2019)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

Short-term outcomes of Early versus conventional adjuvant chemotherapy in stage III colon cancer: randomized clinical trial
por: Lee, Kyung Ha, et al.
Publicado: (2023)

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
por: Moyers, Justin T., et al.
Publicado: (2021)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

Real‐world outcomes of advanced melanoma patients not represented in phase III trials
por: van Zeijl, Michiel C. T., et al.
Publicado: (2020)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile
por: Ikeguchi, Alexandra, et al.
Publicado: (2020)

An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
por: Bensimon, Arielle G., et al.
Publicado: (2020)

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review
por: Mohr, Peter, et al.
Publicado: (2019)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
por: Placzke, Joanna, et al.
Publicado: (2023)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Clinical predictors of survival in real world practice in stage IV melanoma
por: Hu, Hsien‐Pang, et al.
Publicado: (2022)

From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review
por: Kuryk, Lukasz, et al.
Publicado: (2020)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study
por: Kawamura, Hidetaka, et al.
Publicado: (2020)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
por: Helgadottir, Hildur, et al.
Publicado: (2023)

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
por: Amaral, Teresa, et al.
Publicado: (2020)

Real-World Evaluation of Modern Adjuvant Radiotherapy in Women with Stage IB Endometrial Cancer
por: Chen, Jenny Ling-Yu, et al.
Publicado: (2021)

Real-world evidence for option value in metastatic melanoma
por: Wong, William B, et al.
Publicado: (2021)

Considering adjuvant therapy for stage II melanoma
por: Poklepovic, Andrew S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ljam9q9csg3l1rjkerc0mmrui3